Nurse Practitioner in Eagle Butte, SD Accepting Medicare

6 Nurse Practitioner nurses found. Showing 1 - 6

Carla Ann Schweitzer, CN P Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 8000 E Hwy 212, Eagle Butte, SD 57625 Phone: 605-964-8000    Fax: 605-964-1118

Mrs. Kathleeen Kae Zambo, CNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 24276 Airport Road, Eagle Butte, SD 57625 Phone: 605-964-7724    Fax: 605-964-1110

Susan F Baker, CNP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: Ihs Main Street, Eagle Butte, SD 57625 Phone: 605-964-3004    Fax: 605-964-1110

Matthew Raymond Blumer, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 24276 166th St. Airport Road, Eagle Butte, SD 57625 Phone: 605-964-7724

Deleen Jean Kougl, CNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 315 Main Street, Eagle Butte, SD 57625 Phone: 605-964-7700    Fax: 605-964-7701

Amanda Wortman, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 24276 166th St, Airport Rd, Eagle Butte, SD 57625 Phone: 605-964-7724

News Archive

pSivida receives full payment of $15M note from Alimera Sciences

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).

SemBioSys Genetics granted immunoglobulin related patent

SemBioSys Genetics has announced it has been granted U.S. patent 7,098,383 entitled "Methods for the production of multimeric immunoglobulins, and related compositions".

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Antares Pharma, Inc. announced today positive results from its Phase 3 study of Anturol Gel in patients with overactive bladder. The study met its primary endpoint of a statistically significant reduction in urinary incontinence episodes for both doses studied.

Oncolytics signs equity distribution agreement with Canaccord Genuity

Oncolytics Biotech Inc. announced today that it has entered into an "at-the-market" (ATM) equity distribution agreement with Canaccord Genuity Inc. acting as sole agent.

Research: Drug developed for controlling cholesterol synthesis can kill human breast cancer cells

A University of Missouri researcher believes there could be a new drug compound that could kill breast cancer cells. The compound might also help with controlling cholesterol.

Read more Medical News

› Verified 2 days ago